Pioineers in Circulating Tumor Cells (CTCs) Detection and Analysis
Tumors can develop 5 to 10 years before they are detected by imaging, yet Circulating tumor DNA (ctDNA) are already present in the bloodstream from the earliest stages.
At Rarecells, we pioneered the science of isolating these rare cells — creating a new paradigm for early cancer detection.
Rarecells’ proprietary ISET® (Isolation by Size of Tumor cells) platform is a CE-Marked In Vitro Diagnostic (CE-IVD) technology with unparalleled sensitivity. ISET® has the ability to extract down to a single cancer cell from among 50 billion blood cells in a 10 ml blood sample: a CE-validated breakthrough also confirmed in independent studies.
ISET® has been proven to detect cancer before imaging in a groundbreaking independent study, transforming the timeline of cancer diagnosis.
Liquid biopsy has revolutionized cancer diagnostics, primarily through circulating tumor DNA (ctDNA) analysis. However, ctDNA alone has limitations in early-stage disease, where release of ctDNA is absent or barely detectable.
Rarecells’ next generation ISET® CTC-DNA workflow overcomes these limits. By combining the analysis of CTC-DNA and ctDNA from the same stabilized blood sample (standard Streck® tubes). ISET® delivers superior sensitivity, broader genomic coverage, and a complete picture of tumor heterogeneity.
In a recent Rarecells’ clinical study, the combined analysis of both CTC-DNA and ctDNA demonstrated dramatically improved sensitivity and revealed a richer genomic hetergeneity as compared to ctDNA alone, paving the way for mroe effective early detection and recurrence monitoring.
Enhancing the Accuracy of Liquid Biopsy
A Strong Foundation of Scientific Validation
ISET®’s technology is backed by an extensive body of independent, peer-reviewed evidence. With over 125 publications and 6,000 patients studied across 20 types of cancer, ISET® has proven outstanding sensitivity and specificity in applications ranging from :
- Early cancer detection
- Minimal residual disease (MRD) monitoring
- Cancer prognosis and recurrence tracking
- Theranostic and personalized treatment development
Rarecells’ technology is not only scientifically validated — it is alreday changing clinical practice, redefining how and when cancer can be detected.